Hepatotoxicity in Advanced Cancer Patients Receiving Immune-Based Cancer Treatment.
Anas Alshawa,Takeo Fujii,Hamzah Abu Sbeih,Boris Blechacz,Mehmet Asim Bilen,Kenneth R. Hess,Maria E. Suarez-Almazor,David S. Hong,Apostolia Maria Tsimberidou,Jing Gong,Bettzy Stephen,Vivek Subbiah,Sarina Anne Piha-Paul,Siqing Fu,Tito R. Mendoza,Selvi Thirumurthi,Funda Meric-Bernstam,Aung Naing,Ethan Miller
DOI: https://doi.org/10.1200/jco.2018.36.5_suppl.67
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:67 Background: Immune-based cancer treatment (IBCT) is increasingly used to treat a variety of cancers. Despite the promising results, adverse events such as dermatitis, colitis, and hepatitis remain a concern. Hepatitis is usually mild but may be severe, requiring modification or cessation of treatment. Here, we describe several cases of immune-mediated hepatitis. Methods: We identified patients enrolled in clinical trials using IBCT through the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, between January 2010 and July 2015. Charts were reviewed for mention of “autoimmune hepatitis”, “hepatitis” or abnormal transaminases, all of which were attributed to IBCT by the treating physician. Hepatotoxicity was graded based on CTCAE v4.0. Results: We identified 12 cases of immune-related hepatotoxicity out of 290 patients. Three patients (1.03%) had grade 3 elevation of transaminases, designated as “autoimmune hepatitis.” Each required systemic steroids and transaminases returned to baseline within a month. IBCT was temporarily held in 2 cases and was permanently discontinued in the third due to grade 4 myositis rather than hepatitis. One patient (0.3%) had grade 2, and eight patients (2.8%) had grade 1 transaminases elevations that were possibly attributable to immunotherapy, but which resolved spontaneously without alteration in treatment. Other significant reported immune-related toxicities ≥ grade 3 were: dermatitis (n = 4), enterocolitis (n = 3), myasthenia gravis (n = 2), myositis (n = 2), pneumonitis, pleuritis, and pancreatitis (n = 1 each). Conclusions: 1.03% of patients experienced grade 3 elevation of transaminases that were attributable to immune therapy. Hepatic adverse events related to immunotherapy in our study were manageable. Further studies are needed to develop biomarkers to identify patients at risk to develop such toxicities. [Table: see text]